Literature DB >> 27839510

Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.

Hongyu Wang1,2, Xin Li1, David E Volk1,2, Ganesh L-R Lokesh1, Miguel-Angel Elizondo-Riojas1, Li Li1, Alpa M Nick3, Anil K Sood3,4, Kevin P Rosenblatt1,5, David G Gorenstein1,2.   

Abstract

High affinity aptamer-based biomarker discovery has the advantage of simultaneously discovering an aptamer affinity reagent and its target biomarker protein. Here, we demonstrate a morphology-based tissue aptamer selection method that enables us to use tissue sections from individual patients and identify high-affinity aptamers and their associated target proteins in a systematic and accurate way. We created a combinatorial DNA aptamer library that has been modified with thiophosphate substitutions of the phosphate ester backbone at selected 5´dA positions for enhanced nuclease resistance and targeting. Based on morphological assessment, we used image-directed laser microdissection (LMD) to dissect regions of interest bound with the thioaptamer (TA) library and further identified target proteins for the selected TAs. We have successfully identified and characterized the lead candidate TA, V5, as a vimentin-specific sequence that has shown specific binding to tumor vasculature of human ovarian tissue and human microvascular endothelial cells. This new Morph-X-Select method allows us to select high-affinity aptamers and their associated target proteins in a specific and accurate way, and could be used for personalized biomarker discovery to improve medical decision-making and to facilitate the development of targeted therapies to achieve more favorable outcomes.

Entities:  

Keywords:  laser microdissection; morphology-based tissue aptamer selection; ovarian cancer; targeted protein; thioaptamer

Mesh:

Substances:

Year:  2016        PMID: 27839510      PMCID: PMC5136366          DOI: 10.2144/000114473

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  39 in total

1.  In vitro selection of structure-switching signaling aptamers.

Authors:  Razvan Nutiu; Yingfu Li
Journal:  Angew Chem Int Ed Engl       Date:  2005-02-04       Impact factor: 15.336

2.  Chromatin immunoprecipitation (ChIP).

Authors:  Michael F Carey; Craig L Peterson; Stephen T Smale
Journal:  Cold Spring Harb Protoc       Date:  2009-09

3.  Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis.

Authors:  Hiroyuki Jin; Satoko Morohashi; Fuyuki Sato; Yasuyuki Kudo; Harue Akasaka; Shinji Tsutsumi; Hiroshi Ogasawara; Keiichi Miyamoto; Naoki Wajima; Hitoshi Kawasaki; Kenichi Hakamada; Hiroshi Kijima
Journal:  Biomed Res       Date:  2010-04       Impact factor: 1.203

4.  Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis.

Authors:  Y Byun; F Chen; R Chang; M Trivedi; K J Green; V L Cryns
Journal:  Cell Death Differ       Date:  2001-05       Impact factor: 15.828

5.  Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

Authors:  Susan M Fennewald; Erin P Scott; Lihong Zhang; Xianbin Yang; Judith F Aronson; David G Gorenstein; Bruce A Luxon; Robert E Shope; David W C Beasley; Alan D T Barrett; Norbert K Herzog
Journal:  J Gen Virol       Date:  2007-03       Impact factor: 3.891

6.  Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting.

Authors:  Aman P Mann; Anoma Somasunderam; René Nieves-Alicea; Xin Li; Austin Hu; Anil K Sood; Mauro Ferrari; David G Gorenstein; Takemi Tanaka
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

7.  Transactivation of vimentin by beta-catenin in human breast cancer cells.

Authors:  Christine Gilles; Myriam Polette; Mélanie Mestdagt; Béatrice Nawrocki-Raby; Philippe Ruggeri; Philippe Birembaut; Jean-Michel Foidart
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Glycoproteomic analysis of human lung adenocarcinomas using glycoarrays and tandem mass spectrometry: differential expression and glycosylation patterns of vimentin and fetuin A isoforms.

Authors:  Jung-Hyun Rho; Michael H A Roehrl; Julia Y Wang
Journal:  Protein J       Date:  2009-05       Impact factor: 2.371

9.  The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

Authors:  Eberhard Korsching; Jens Packeisen; Cornelia Liedtke; Daniela Hungermann; Pia Wülfing; Paul J van Diest; Burkhard Brandt; Werner Boecker; Horst Buerger
Journal:  J Pathol       Date:  2005-08       Impact factor: 7.996

10.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18
View more
  11 in total

1.  Identification of Vigilin as a Potential Ischemia Biomarker by Brain Slice-Based Systematic Evolution of Ligands by Exponential Enrichment.

Authors:  Chao Liu; Wei Jiang; Xibin Tian; Peng Yang; Le Xiao; Jianglin Li; Liping Qiu; Haijun Tu; Weihong Tan
Journal:  Anal Chem       Date:  2019-05-01       Impact factor: 6.986

2.  X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia.

Authors:  Consuelo Walss-Bass; Ganesh L R Lokesh; Elena Dyukova; David G Gorenstein; David L Roberts; Dawn Velligan; David E Volk
Journal:  Mol Neuropsychiatry       Date:  2018-10-10

3.  Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.

Authors:  Burak Kucuk; Esra Yilmaz; Ercan Cacan
Journal:  Mol Biol Rep       Date:  2021-05-19       Impact factor: 2.316

Review 4.  Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers.

Authors:  Marie-Cécile Mercier; Monique Dontenwill; Laurence Choulier
Journal:  Cancers (Basel)       Date:  2017-06-21       Impact factor: 6.639

5.  Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Authors:  Valeriy Domenyuk; Zoran Gatalica; Radhika Santhanam; Xixi Wei; Adam Stark; Patrick Kennedy; Brandon Toussaint; Symon Levenberg; Jie Wang; Nianqing Xiao; Richard Greil; Gabriel Rinnerthaler; Simon P Gampenrieder; Amy B Heimberger; Donald A Berry; Anna Barker; John Quackenbush; John L Marshall; George Poste; Jeffrey L Vacirca; Gregory A Vidal; Lee S Schwartzberg; David D Halbert; Andreas Voss; Daniel Magee; Mark R Miglarese; Michael Famulok; Günter Mayer; David Spetzler
Journal:  Nat Commun       Date:  2018-03-23       Impact factor: 14.919

Review 6.  Development of Phosphorothioate DNA and DNA Thioaptamers.

Authors:  David E Volk; Ganesh L R Lokesh
Journal:  Biomedicines       Date:  2017-07-13

Review 7.  Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.

Authors:  Sven Kruspe; Paloma H Giangrande
Journal:  Biomedicines       Date:  2017-08-09

Review 8.  Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Authors:  Mayte Sola; Ashwathi Puravankara Menon; Beatriz Moreno; Daniel Meraviglia-Crivelli; Mario Martínez Soldevilla; Fernando Cartón-García; Fernando Pastor
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-23       Impact factor: 8.886

Review 9.  Current and future advances in fluorescence-based visualization of plant cell wall components and cell wall biosynthetic machineries.

Authors:  Brian T DeVree; Lisa M Steiner; Sylwia Głazowska; Felix Ruhnow; Klaus Herburger; Staffan Persson; Jozef Mravec
Journal:  Biotechnol Biofuels       Date:  2021-03-29       Impact factor: 6.040

Review 10.  Antibodies, Nanobodies, or Aptamers-Which Is Best for Deciphering the Proteomes of Non-Model Species?

Authors:  Poshmaal Dhar; Rasika M Samarasinghe; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2020-04-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.